Plain-English translation of NCT05603559 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing two new versions of a radioactive treatment called 177Lu-P17-087 and 177Lu-P17-088 for men with advanced prostate cancer that has stopped responding to standard treatments. These medications work by targeting a specific protein found on prostate cancer cells, then delivering radiation directly to tumors. Researchers want to understand how safe these treatments are, how the body handles them, and what dose works best.
Current radioactive treatments for advanced prostate cancer work but have a major limitation—they clear from the body too quickly, which may reduce how effective they can be. This trial is testing whether the new versions of this medication stay in the body longer and work better against the cancer.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of the experimental medication through your vein. After the injection, you will have check-in visits and scans at specific time points over the next week (at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours, and 168 hours after treatment). These visits will help researchers measure how the medication moves through your body, check for any side effects, and see how well it's working against your cancer.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China